Relationship between gender and survival in a real-life cohort of patients with COPD.


Journal

Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633

Informations de publication

Date de publication:
22 Aug 2019
Historique:
received: 16 02 2019
accepted: 05 08 2019
entrez: 24 8 2019
pubmed: 24 8 2019
medline: 8 2 2020
Statut: epublish

Résumé

Although COPD affects both men and women, its prevalence is increasing more rapidly in women. Disease outcomes appear different among women with more frequent dyspnea and anxiety or depression but whether this translates into a different prognosis remains to be determined. Our aim was to assess whether the greater clinical impact of COPD in women was associated with differences in 3-year mortality rates. In the French Initiatives BPCO real-world cohort, 177 women were matched up to 458 menon age (within 5-year intervals) and FEV For a given age and level of airflow obstruction, women with COPD had more severe dyspnea, lower BMI, and were more likely to exhibit anxiety. Nevertheless, three-year mortality rate was comparable among men and women, respectively 11.2 and 10.8%. In a multivariate model, the only factors significantly associated with mortality were dyspnea and malnutrition but not gender. Although women with COPD experience higher levels of dyspnea and anxiety than men at comparable levels of age and FEV1, these differences do not translate into variations in 3-year mortality rates. 04-479.

Sections du résumé

BACKGROUND BACKGROUND
Although COPD affects both men and women, its prevalence is increasing more rapidly in women. Disease outcomes appear different among women with more frequent dyspnea and anxiety or depression but whether this translates into a different prognosis remains to be determined. Our aim was to assess whether the greater clinical impact of COPD in women was associated with differences in 3-year mortality rates.
METHODS METHODS
In the French Initiatives BPCO real-world cohort, 177 women were matched up to 458 menon age (within 5-year intervals) and FEV
RESULTS RESULTS
For a given age and level of airflow obstruction, women with COPD had more severe dyspnea, lower BMI, and were more likely to exhibit anxiety. Nevertheless, three-year mortality rate was comparable among men and women, respectively 11.2 and 10.8%. In a multivariate model, the only factors significantly associated with mortality were dyspnea and malnutrition but not gender.
CONCLUSION CONCLUSIONS
Although women with COPD experience higher levels of dyspnea and anxiety than men at comparable levels of age and FEV1, these differences do not translate into variations in 3-year mortality rates.
TRIAL REGISTRATION BACKGROUND
04-479.

Identifiants

pubmed: 31439045
doi: 10.1186/s12931-019-1154-3
pii: 10.1186/s12931-019-1154-3
pmc: PMC6704674
doi:

Types de publication

Letter

Langues

eng

Sous-ensembles de citation

IM

Pagination

191

Subventions

Organisme : CSRD VA
ID : 1
Pays : United States

Investigateurs

P R Burgel (PR)
G Deslee (G)
P Surpas (P)
O Le Rouzic (O)
T Perez (T)
N Roche (N)
G Brinchault-Rabin (G)
D Caillaud (D)
P Chanez (P)
I Court-Fortune (I)
R Escamilla (R)
G Jebrak (G)
P Nesme-Meyer (P)
M Zysman (M)
C Pinet (C)
Brigitte Risse (B)

Références

Chest. 2001 Jun;119(6):1691-5
pubmed: 11399692
Chest. 2002 May;121(5):1434-40
pubmed: 12006425
Respir Med. 2006 Oct;100(10):1767-74
pubmed: 16531031
Eur Respir J. 2009 Mar;33(3):528-35
pubmed: 19047315
Eur Respir J. 2010 Sep;36(3):531-9
pubmed: 20075045
Am J Respir Crit Care Med. 2011 Feb 1;183(3):317-22
pubmed: 20813884
Respir Med. 2012 Mar;106(3):367-73
pubmed: 22018505
Respir Res. 2014 Feb 17;15:20
pubmed: 24533770
BMC Womens Health. 2014 Feb 20;14(1):31
pubmed: 24555562
Int J Chron Obstruct Pulmon Dis. 2014 Oct 14;9:1145-54
pubmed: 25342899
Chest. 2017 Mar;151(3):686-696
pubmed: 27816445
Am J Respir Crit Care Med. 2017 May 1;195(9):1226-1235
pubmed: 28075609
Eur Respir J. 2017 Aug 10;50(2):
pubmed: 28798087
Am J Respir Crit Care Med. 2018 Oct 1;198(7):850-858
pubmed: 29746147
Int J Chron Obstruct Pulmon Dis. 2018 Oct 01;13:3021-3029
pubmed: 30319250
Int J Chron Obstruct Pulmon Dis. 2018 Oct 17;13:3389-3398
pubmed: 30410324

Auteurs

Maeva Zysman (M)

Pulmonary Department, Nancy, France. maeva55@club-internet.fr.
Inserm U955, team 04, IMRB, Créteil, France. maeva55@club-internet.fr.
Maéva Zysman 8 rue du général sarrail, 94000, Creteil, France. maeva55@club-internet.fr.

Pierre-Régis Burgel (PR)

Respiratory and Intensive Care Medicine Department, Cochin Hospital, AP-HP and Paris Descartes University (EA 2511), Sorbonne Paris Cité, Paris, France.

Isabelle Court-Fortune (I)

Service de Pneumologie, CHU Saint Etienne, Saint Etienne, France.

Graziella Brinchault-Rabin (G)

Service de Pneumologie, Hôpital Pontchaillou, Rennes, France.

Pascale Nesme-Meyer (P)

Service de Pneumologie, Hôpital de la Croix-Rousse, Lyon, France.

Pascale Surpas (P)

Centre médical de Bayère, 30, route du Vieux-Château, 69380, Charnay, France.

Gaetan Deslée (G)

Pulmonary Department, Maison Blanche University Hospital, INSERM U01250, Reims, France.

Thierry Perez (T)

Univ.Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France.

Olivier Le Rouzic (O)

Univ.Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 8204 - CIIL - Center for Infection and Immunity of Lille, F-59000, Lille, France.

Gilles Jebrak (G)

Service de Pneumologie, Hôpital Bichat, AP-HP, Paris, France.

Pascal Chanez (P)

Département des Maladies Respiratoires, AP-HM, Université de la Méditerranée, Marseille, France.

Jean-Louis Paillasseur (JL)

EFFI-STAT, Paris, France.

Denis Caillaud (D)

Service de Pneumologie, Hôpital Gabriel Montpied, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Nicolas Roche (N)

Respiratory and Intensive Care Medicine Department, Cochin Hospital, AP-HP and Paris Descartes University (EA 2511), Sorbonne Paris Cité, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH